Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sorafenib tosylate works in treating patients with
progressive metastatic neuroendocrine tumors. Sorafenib tosylate may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to
the tumor.